Imexpharm Corporation (HOSE:IMP)

Vietnam · Delayed Price · Currency is VND

42,950

+250 (0.59%)

At close: Jul 3, 2026

-17.40% (1Y)

Market Cap	6.61T -16.8%
Revenue (ttm)	2.39T +3.7%
Net Income	311.12B +7.0%
EPS	2,020.16 +8.6%
Shares Out	154.01M
PE Ratio	21.26
Forward PE	18.64
Dividend	500.00 (1.17%)
Ex-Dividend Date	Jul 13, 2026

Volume	13,451
Open	42,950
Previous Close	42,700
Day's Range	42,850 - 43,150
52-Week Range	41,100 - 57,000
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietna... [Read more]

Industry Pharmaceutical Preparations

Founded 1997

Employees 1,444

Stock Exchange Ho Chi Minh Stock Exchange

Ticker Symbol IMP

Full Company Profile

Financial Performance

In 2025, Imexpharm's revenue was 2.44 trillion, an increase of 10.70% compared to the previous year's 2.21 trillion. Earnings were 304.39 billion, an increase of 10.34%.

Financial Statements